NovoCure
NVCR
71 hedge funds and large institutions have $172M invested in NovoCure in 2017 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 26 reducing their positions, and 12 closing their positions.
6,819% more call options, than puts
Call options by funds: $6.99M | Put options by funds: $101K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
4% more capital invested
Capital invested by funds: $166M → $172M (+$6.4M)
0.24% less ownership
Funds ownership: 24.32% → 24.08% (-0.24%)
9% less funds holding
Funds holding: 78 → 71 (-7)
17% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 12
42% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$24.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.35M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$1.2M |
| 4 |
RGI
River Global Investors
London,
United Kingdom
|
+$838K |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
+$603K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.25M |
| 2 |
Morgan Stanley
New York
|
-$713K |
| 3 |
Barclays
London,
United Kingdom
|
-$401K |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$393K |
| 5 |
Citigroup
New York
|
-$355K |
NVCR Hedge Fund Activity: Q1 2017 in Review
71 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q1 2017, worth a combined $172M — up 3.9% from $166M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of NVCR and 10 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 15 added.
The largest buyer was BlackRock, adding an estimated $24.7M. The largest seller was Fidelity Investments, cutting an estimated $2.25M.
- 71 institutional investors held NovoCure (NVCR) as of Q1 2017, down from 78 in Q4 2016.
- Funds reported $172M of NovoCure stock for Q1 2017, up 3.9% quarter-over-quarter.
- 10 funds opened new NovoCure positions in Q1 2017 and 12 closed out, a net change of -2 holders.
- The largest NovoCure buyer in Q1 2017 was BlackRock, an estimated $24.7M added.
- The largest NovoCure seller in Q1 2017 was Fidelity Investments, an estimated $2.25M sold.
Based on aggregated 13F filings for Q1 2017.